EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Utility of the PROSTest, a Novel Blood‐Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease

Mark Kidd, Grzegorz Rempega, Michal Kepinski iD, Szymon Slomian, Krystyna Mlynarek, Abdel B Halim

The Prostate · 2026

DOI: 10.1002/pros.70086 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Prostate, 2026. Verfasst von Mark Kidd und 5 weiteren Autor:innen. Beteiligte Einrichtung: Wren Laboratories, Branford, Connecticut, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This work was supported in part by Wren Laboratories provided free sample measurement..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate cancer (PCa) is the most common solid organ cancer in men and the fifth leading cause of cancer‐related deaths globally. PSA helps identify men at risk but has low specificity and has resulted in unnecessary biopsies. The PROSTest, a novel machine learning‐based 27‐gene mRNA liquid biopsy assay, was developed to detect PCa. We evaluated its utility as a stratification tool in symptomatic men undergoing biopsy or surgery for PSA > 2 ng/mL.

Methods

Of 123 men assessed, 105 (85%) met eligibility criteria (age > 55 years, PSA > 2 ng/mL, symptomatic) and underwent image‐guided biopsy or surgery. Blood samples for PROSTest were collected prebiopsy, and RNA‐stabilized samples underwent RNA isolation and cDNA production. PCR results were analyzed using a machine learning algorithm, generating a 0–100 score with a cutoff of 50 for a binary (positive/negative) readout. The performance of PROSTest was against PSA using AUROC and evaluated for Gleason Grade (GG) 1 versus GG2–5 patients.

Results

Median age was 68 years (55–86 years); median PSA was 8.2 ng/mL (IQR: 7.2–92 ng/mL). PCa was diagnosed in 65 men (62%) (27 GG1; 38 GG2–5). PROSTest was positive in 63/65 (97%) of those with PCa and in 2/40 (5%) without PCa. Sensitivity was 97%, specificity 96%. PROSTest outperformed PSA (AUROC: 0.99 vs. 0.61, p < 0.0001). GG2–5 had significantly higher ( p < 0.0001) PROSTest scores (92 ± 3).

Conclusions

PROSTest demonstrated superior sensitivity and specificity compared to PSA for detecting prostate cancer across all Gleason grades. Additionally, it showed potential for distinguishing GG2–5 from GG1 + BPH, which could help guide clinical decision‐making and reduce unnecessary biopsies. By leveraging a machine learning‐based approach, PROSTest may offer a more accurate and less invasive diagnostic tool for prostate cancer stratification. However, larger prospective studies are needed to validate these findings and further define its clinical utility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstate-Specific AntigenHumansMaleMiddle AgedAgedMachine LearningNeoplasm GradingLiquid BiopsySensitivity and SpecificityBiomarkers, TumorAged, 80 and over

Stichwörter der Autor:innen

PCRPROSTestPSAprostate cancerscreening

Substanzen

Prostate-Specific AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Wren Laboratories, Branford, Connecticut, USA.
  • Department of Urology, Medical University of Silesia, Katowice, Poland.
  • Department of Urology, Regional Specialist Hospital No. 3, Rybnik, Poland.

ORCID-Profile: Michal Kepinski

Förderung

  • This work was supported in part by Wren Laboratories provided free sample measurement.

Zitieren

APA

Kidd, M., Rempega, G., Kepinski, M., Slomian, S., Mlynarek, K., & Halim, A. B. (2026). Utility of the PROSTest, a Novel Blood‐Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease. The Prostate. https://doi.org/10.1002/pros.70086

Vancouver

Kidd M, Rempega G, Kepinski M, Slomian S, Mlynarek K, Halim AB. Utility of the PROSTest, a Novel Blood‐Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease. The Prostate. 2026. doi:10.1002/pros.70086

BibTeX
@article{Kidd2026,
  author = {Kidd, Mark and Rempega, Grzegorz and Kepinski, Michal and Slomian, Szymon and Mlynarek, Krystyna and Halim, Abdel B},
  title = {Utility of the PROSTest, a Novel Blood‐Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease},
  journal = {The Prostate},
  year = {2026},
  doi = {10.1002/pros.70086}
}
Kostenlos starten →